Diffuse Large B Cell Lymphoma  >>  Gazyva (obinutuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

33 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
GATHER, NCT01414855: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma

Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Completed
2
100
US
obinutuzumab, cyclophosphamide, doxorubicin, prednisone, vincristine
Genentech, Inc.
Lymphoma, B-Cell
12/13
12/16
2015-005273-20: Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffuse Large B-cell Lymphoma (DLBCL) patients. Studio multicentrico di fase II a braccio singolo sulla fattibilit¿, sicurezza ed efficacia della combinazione CHOP-21 con Obinutuzumab e Ibrutinib come terapia di prima linea in pazienti giovani ad alto rischio affetti da linfoma a grandi cellule B.

Not yet recruiting
2
90
Europe
Imbruvica, Ibrutinib, Concentrate for solution for infusion, Capsule, hard, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (90 CAPSULE RIGIDE)
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche, Janssen - Cilag
Diffuse Large B-Cell lymphoma (DLBCL) Linfoma a grandi cellule B (DLBCL), Diffuse Large B-Cell lymphoma Linfoma a grandi cellule B, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02420210: Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

Terminated
2
2
US
Bendamustine Hydrochloride, Ribomustin, SyB L-0501, Treanda, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA101, Gazyva, R7159, RO 5072759, Dexamethasone, DM, Quality-of-Life Assessment, Quality of Life Assessment, Laboratory Biomarker Analysis
University of Chicago, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma
08/16
08/16
FIL-GALILEO, NCT02670317: Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.

Terminated
2
1
Europe
Obinutuzumab, GA101, Ibrutinib, Imbruvica, CHOP, Cyclophosphamide, doxorubicin, vincristine, and prednisone, Hydroxydaunomycin, Oncovin
Fondazione Italiana Linfomi ONLUS
Lymphoma, B-Cell
02/17
02/17
ROMULUS, NCT01691898 / 2011-004377-84: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Checkmark ROMULUS trial of polatuzumab + Gazyva/Rituxan for r/r FL and DLBCL at ASH 2016
Dec 2016 - Dec 2016: ROMULUS trial of polatuzumab + Gazyva/Rituxan for r/r FL and DLBCL at ASH 2016
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ROMULUS trial for NHL
More
Completed
2
231
Europe, Canada, US
Obinutuzumab, GA101, Gazyva, Gazyvaro, Pinatuzumab Vedotin, DCDT2980S, Polatuzumab Vedotin, DCDS4501A, Rituximab, MabThera/Rituxan
Genentech, Inc.
Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
03/17
02/19
FIL_GAEL, NCT02495454 / 2014-005697-10: GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma

Terminated
2
34
Europe
Ga101, Obinutuzumab
Fondazione Italiana Linfomi ONLUS
CD20 Positive Diffuse Large B-cell Lymphoma, Elderly Unfit Patients
03/17
03/17
GIOTTO, NCT02374424 / 2013-004014-17: Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients

Terminated
2
29
Europe
GA101_DHAP
Fondazione Italiana Linfomi ONLUS
Diffuse, Large B-Cell, Lymphoma
02/18
06/20
LYSA, NCT03276468 / 2016-005061-31: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Completed
2
136
Europe
Atezolizumab, Tecentriq, Obinutuzumab, Gazyvaro, Venetoclax, Venclyxto
The Lymphoma Academic Research Organisation
Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue
09/19
08/22
NCT02987400 / 2016-001760-10: Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

Completed
2
22
Europe
Venetoclax, GA-101, Obinutuzumab, Gazyvaro
Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG
Lymphoma, Large B-Cell, Diffuse
10/21
10/21
2022-003398-51: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dose R-CHOP Eine prospektive, multizentrische Phase-2-Studie zur chemotherapiearmen Kombination von Rituximab mit dem Antikörper-Wirkstoff-Konjugat Polatuzumab Vedotin und dem bispezifischen Antikörper Glofitamab bei zuvor unbehandelten Patienten mit aggressivem B-Zell-Lymphom über 60 Jahren, die für ein voll dosiertes R-CHOP nicht in Frage kommen

Not yet recruiting
2
80
Europe
Glofitamab, Obinutuzumab, Polatuzumab vedotin, Rituximab, RO7082859, RO5072759, RO5541077, RO0452294, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Columvi, GAZYVARO, Polivy, MabThera
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Roche Pharma AG, Roche Austria GmbH
aggressive large B-cell lymphoma, aggressive large B-cell lymphoma, Diseases [C] - Cancer [C04]
 
 
BiCAR, NCT04703686 / 2020-001985-12: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Active, not recruiting
2
67
Europe
Obinutuzumab, gazyva, RO7082859, glofitamab
The Lymphoma Academic Research Organisation
Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Refractory Mantle Cell Lymphoma
01/23
03/26
NCT05823701: Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

Recruiting
2
23
RoW
Chidamide, Tucidinostat, Azacitidine, AZA, obinutuzumab, Gazyva, Liposomal mitoxantrone, PLM60
The First Affiliated Hospital of Soochow University
Diffuse Large B-Cell Lymphoma
12/23
12/25
NCT03401853: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Active, not recruiting
2
18
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, rituximab biosimilar TQB2303, rituximab-abbs, Truxima, Rituximab Biosimilar SIBP-02, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
University of Washington, Merck Sharp & Dohme LLC
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
12/23
12/25
NCI-2024-00209, NCT06213311: A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Recruiting
2
40
US
Glofitamab, RO7082859, RG6026, Obinutuzumab, GA101, Gazyva, RO5072759, Axi-cel, Axicabtagene ciloleucel, KTE-C19, KTE-X19
M.D. Anderson Cancer Center, Genentech, Inc., Kite, A Gilead Company
B Cell Lymphoma
01/25
01/27
O-ICE, NCT02393157: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Recruiting
2
25
US
Obinutuzumab, Gazyva, Liposomal ARA-C, Depocyte, Ifosfamide, Ifex, Carboplatin, Paraplatin, Etoposide, VP-16
New York Medical College, Roswell Park Cancer Institute
Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
12/24
12/24
UPCC 48420, NCT04889716: CAR-T Followed by Bispecific Antibodies

Recruiting
2
42
US
mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101
Abramson Cancer Center at Penn Medicine, Genentech, Inc.
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
12/24
12/25
R-Pola-Glo, NCT05798156: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting
2
80
Europe
Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
09/27
09/28
PORTAL, NCT06071871: A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Not yet recruiting
2
99
NA
Glofitamab, Columvi, Polatuzumab vedotin, Polivy, Obinutuzumab, Gazyvaro
University College, London, Hoffmann-La Roche
Large B-cell Lymphoma
01/27
07/28
CAVALLI, NCT02055820 / 2013-003749-40: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Checkmark CAVALLI trial in combination with rituximab or obinutuzumab + CHOP in front-line DLBCL at ASH 2016
Dec 2016 - Dec 2016: CAVALLI trial in combination with rituximab or obinutuzumab + CHOP in front-line DLBCL at ASH 2016
Checkmark CAVALLI trial in combination with rituximab or obinutuzumab + CHOP in first-line aggressive NHL at ASCO 2016
Jun 2016 - Jun 2016: CAVALLI trial in combination with rituximab or obinutuzumab + CHOP in first-line aggressive NHL at ASCO 2016
Completed
1/2
267
Europe, Canada, US, RoW
Venetoclax, GDC-0199, ABT-199, Cyclophosphamide, Obinutuzumab, Rituximab, MabThera/Rituxan, Doxorubicin, Vincristine, Prednisone
Hoffmann-La Roche, AbbVie
Lymphoma, Non-Hodgkin
06/17
06/19
NCT02596971 / 2015-001364-19: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Results for Tecentriq in combination with obinutuzumab-bendamustine chemoimmunotherapy regimen for 1L follicular lymphoma
Nov 2022 - Nov 2022: Results for Tecentriq in combination with obinutuzumab-bendamustine chemoimmunotherapy regimen for 1L follicular lymphoma
Checkmark Initiation with atezolizumab in combination with Gazyva and bendamustine for FLL/DLBCL
Nov 2015 - Nov 2015: Initiation with atezolizumab in combination with Gazyva and bendamustine for FLL/DLBCL
Checkmark Initiation in atezolizumab in combination with Gazyva and CHOP for DLBCL
More
Completed
1/2
91
Europe, US, RoW
Atezolizumab, RO5541267; Tecentriq, Bendamustine, Cyclophosphamide, Doxorubicin, Obinutuzumab, RO5072759, Prednisone, Vincristine, Rituximab
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
04/18
05/20
NCT01582776 / 2011-005150-62: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma

Completed
1/2
317
Europe
Lenalidomide and GA101, Revlimid, Obinutuzumab
The Lymphoma Academic Research Organisation
Follicular Lymphoma Patients (Phase IB), Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)
07/18
05/22
NCT02729896 / 2015-004845-25: A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark First patient in P1/2 trial of Tecentriq + Rituxan + polatuzumab for DLBCL
Jun 2016 - Jun 2016: First patient in P1/2 trial of Tecentriq + Rituxan + polatuzumab for DLBCL
Completed
1/2
36
Europe, US
Atezolizumab [TECENTRIQ], Obinutuzumab, Polatuzumab Vedotin, Rituximab
Hoffmann-La Roche
Lymphoma
09/18
10/19
NCT02624986 / 2015-002100-83: A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Terminated
1/2
25
Europe, US, RoW
Idasanutlin, RO5503781, Obinutuzumab, RO5072759, Rituximab, RO0452294
Hoffmann-La Roche
Non-Hodgkin's Lymphoma
05/19
05/19
NCT03135262 / 2016-002480-34: A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated
1/2
29
Europe, US, RoW
Idasanutlin, Obinutuzumab, Venetoclax, Rituximab
Hoffmann-La Roche
Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse
04/20
04/20
GO29365, NCT02257567 / 2014-001361-28: A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Checkmark Regulatory approval in Japan in combination with bendamustine and rituximab for relapsed/refractory DLBCL
Mar 2021 - Mar 2021: Regulatory approval in Japan in combination with bendamustine and rituximab for relapsed/refractory DLBCL
Checkmark Subgroup analysis data from trial for r/r DLBCL at ASH 2020
Dec 2020 - Dec 2020: Subgroup analysis data from trial for r/r DLBCL at ASH 2020
Checkmark Data from trial for r/r DLBCL at ASH 2020
More
Completed
1/2
331
Europe, Canada, US, RoW
Bendamustine, Treanda; Ribomustin; Levact, Obinutuzumab, GA101; Gazyva; Gazyvaro, Polatuzumab vedotin (Liquid), DCDS4501A, Rituximab, Rituxan; MabThera, Polatuzumab vedotin (Lyophilized), DCDS4501S
Hoffmann-La Roche
Lymphoma
10/21
10/21
GO29834, NCT02600897 / 2015-001999-22: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Data from trial in combination with mabThera/rituxan and lenalidomide for r/r DLBCL
Jun 2021 - Jun 2021: Data from trial in combination with mabThera/rituxan and lenalidomide for r/r DLBCL
Checkmark From P1/2 trial in combination with Gazvya and lenalidomide in follicular lymphoma at ASCO 2019 [screenshot]
Jun 2019 - Jun 2019: From P1/2 trial in combination with Gazvya and lenalidomide in follicular lymphoma at ASCO 2019 [screenshot]
Completed
1/2
114
Europe, US
Lenalidomide, Obinutuzumab, Polatuzumab Vedotin, Rituximab
Hoffmann-La Roche
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
12/21
12/21
2018-003235-29: An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Not yet recruiting
1/2
348
Europe
CC-99282, Gazyvaro, Tafasitamab, Rituximab, valemetostat, CC-99282, Capsule, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Tablet, MabThera 100 mg concentrate for solution for infusion, Gazyvaro, Monjuvi
Celgene Corporation, Celgene Corporation
Subjects with R/R NHL, which includes diffuse large B-cell lymphoma (DLBCL) (not otherwise specified [NOS] or transformed), FL (follicular lymphoma), mantle cell lymphoma (MCL), primary central nervous system lymphoma (PCNSL) or relapsed or refractory marginal zone lymphoma (MZL) who have failed at least 2 lines of therapy (or who have received at least one prior line of standard therapy and are not eligible for any other therapy)., Patients who have stopped responding or have failed to respond to treatment for cancer of a type of white blood cell., Diseases [C] - Cancer [C04]
 
 
GO29833, NCT02611323 / 2015-001998-40: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

Completed
1/2
133
Europe, US, RoW
Obinutuzumab, Rituximab, Polatuzumab Vedotin, Venetoclax
Hoffmann-La Roche, Genentech Inc. c/o F. Hoffmann La Roche Ltd.
Non-Hodgkin's Lymphoma
08/22
08/22
NCT02529852: A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma

Completed
1/2
59
US
Lenalidomide, CC-5013, Revlimid, Obinutuzumab, GA101, Gazyva, Cyclophosphamide, Cytoxan, Neosar, Doxorubicin, Doxorubicin Hydrochloride, Adriamycin PFS, Adriamycin RDF, Adriamycin, Rubex, Vincristine, Prednisone
M.D. Anderson Cancer Center, Celgene, Genentech, Inc.
Lymphoma
10/22
10/22
ViPOR, NCT03223610: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid () in Relapsed/Refractory B-cell Lymphoma

Recruiting
1/2
145
US
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Revlimid (lenalidomide)
National Cancer Institute (NCI)
Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
12/25
12/26
NP39488, NCT03533283: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting
1/2
280
Europe, US, RoW
Glofitamab, RO7082859, Atezolizumab, Obinutuzumab, Tocilizumab, Actemra, Polatuzumab Vedotin, 89Zr-Df-IAB22M2C
Hoffmann-La Roche
Non-Hodgkins Lymphoma
09/26
09/26
CC-99282-NHL-001, NCT03930953: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Recruiting
1/2
438
Europe, Canada, US, RoW
CC-99282, BMS-986369, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat
Celgene
Lymphoma, Non-Hodgkin
04/26
04/27
C4971006, NCT05896163: A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Recruiting
1/2
70
Japan, US, RoW
maplirpacept (PF-07901801), Glofitamab, Obinutuzumab
Pfizer, Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma
06/26
06/28

Download Options